Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) EBITDA: 2022-2024

Historic EBITDA for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to -$217.3 million.

  • Day One Biopharmaceuticals' EBITDA fell 181.83% to -$24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$165.6 million, marking a year-over-year increase of 21.67%. This contributed to the annual value of -$217.3 million for FY2024, which is 5.44% down from last year.
  • According to the latest figures from FY2024, Day One Biopharmaceuticals' EBITDA is -$217.3 million, which was down 5.44% from -$206.1 million recorded in FY2023.
  • In the past 5 years, Day One Biopharmaceuticals' EBITDA registered a high of -$146.9 million during FY2022, and its lowest value of -$217.3 million during FY2024.
  • Over the past 3 years, Day One Biopharmaceuticals' median EBITDA value was -$206.1 million (recorded in 2023), while the average stood at -$190.1 million.
  • Data for Day One Biopharmaceuticals' EBITDA shows a maximum YoY crashed of 40.27% (in 2023) over the last 5 years.
  • Day One Biopharmaceuticals' EBITDA (Yearly) stood at -$146.9 million in 2022, then crashed by 40.27% to -$206.1 million in 2023, then decreased by 5.44% to -$217.3 million in 2024.